GleamWall
中文EN

LTGO Latigo Biotherapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 2056611 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets3.5%
Debt / equity0.00x
Current ratio29.11x
Interest coverage—

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q32025-09-302025Q22025-06-302025Q12025-03-31
Income statement
Revenue——————
R&D expense$17.50M$21.23M—$22.10M$22.92M—
SG&A expense$5.43M$4.58M—$2.63M$2.82M—
Operating income-$22.93M-$25.81M—-$24.72M-$25.75M—
Interest expense$699,000$251,000—$0$0—
Income tax$0$0—$0$0—
Net income-$20.95M-$25.80M-$22.96M-$24.80M-$25.84M-$20.95M
EBITDA-$22.83M-$25.71M—-$24.62M-$25.64M—
EPS (basic)-0.55-27.59—-29.50-36.52—
EPS (diluted)-0.55-27.59—-29.50-36.52—
Dividends declared per share0.00—————
Weighted avg. shares (diluted)37.84M935,025—840,403707,465—
Balance sheet
Cash & equivalents$401.24M$55.00M—$104.64M$74.50M—
Current assets$406.44M$59.20M————
PP&E, net$440,000$457,000————
Total assets$408.46M$64.76M————
Current liabilities$13.96M$51.58M————
Total liabilities$14.48M$52.26M————
Shareholders' equity$393.97M-$276.08M-$252.58M-$195.85M-$173.23M-$149.08M
Shares outstanding66.30M988,236————
Cash flow statement
Operating cash flow-$19.52M——-$19.91M——
Capital expenditure$36,000——$0——
Free cash flow-$19.56M——-$19.91M——
Investing cash flow-$36,000——$0——
Financing cash flow$365.76M——$50.05M——
Depreciation & amortization$100,000$100,000—$100,000$100,000—
Stock-based compensation$2.54M$2.14M—$1.82M$1.68M—

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.